Polycyclic aromatic hydrocarbons (PAHs) are a group of compounds formed during the incomplete combustion of organic matter. Several are mutagenic carcinogens; the magnitude of exposure can be assessed by examining urinary levels of PAH metabolites. Data from biomonitoring studies that record urinary PAH metabolite levels, as well as demographic and lifestyle information, can be used to investigate relationships between PAH exposure and variables, such as smoking status, workplace smoking restrictions, age, sex, household income, home age, and occupation. This study analysed creatinineadjusted urinary PAH metabolite concentrations and questionnaire data from~1200 individuals aged 16 years and older surveyed in Cycle 2 of the Canadian Health Measures Survey (CHMS). Statistical analyses revealed that smoking status, age, and sex are associated with urinary concentrations of a pyrene metabolite (1-OHP), phenanthrene metabolites (ΣOH-Phen), fluorene metabolites (ΣOH-Flu) and naphthalene metabolites (ΣOH-Nap). More specifically, smoking status, age and sex can collectively account for 30, 24, 52, and 34% of the observed variations in 1-OHP, ΣOH-Phen, ΣOH-Flu and ΣOH-Nap metabolites, respectively (p < 0.001). Analyses of non-smokers revealed weak but significant effects of age, sex, home age, and occupation on urinary levels of selected PAH metabolites (i.e., <7% of observed variation, p < 0.05). The unexplained variation in PAH metabolite levels is most likely related to diet, which was not examined. Although the results revealed significant relationships between urinary PAH metabolite levels and several lifestyle and/or demographic variables, robust examinations of selected effects (e.g., sex, home age, occupation) will require datasets that are balanced with respect to the other highlighted variables. The results can be used to identify remedial measures to reduce exposure and concomitant risk, and/or design follow-up studies to test hypotheses regarding the causes of exposure differences empirically related to sex, age, home age, and occupation.
Introduction
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental contaminants formed during the incomplete combustion of organic matter (e.g., fossil fuels, biomass). Many PAHs are mutagenic, carcinogenic and/or teratogenic, and humans can be exposed via contact with virtually any agent containing combustion-derived substances (e.g., tobacco smoke, urban air, char-broiled foods). The bulk of human exposures occur via dietary intake and contact with tobacco smoke [1] [2] [3] .
Monitoring of urinary PAH metabolite levels constitutes a convenient, non-invasive method to assess an individual's exposure to PAHs, and relatedly, complex PAH-containing matrices. 1-Hydroxypyrene (1-OHP) has been widely used as a biomarker of PAH exposure, yet there is disagreement regarding a recommended benchmark level, particularly for occupational exposures, with values ranging from 1.0 to 2.3 µmol/mol creatinine [4] [5] [6] . Other urinary PAH metabolites have also been used for exposure monitoring. Metabolites of lower molecular weight (MW) PAHs such as phenanthrene, fluorene, anthracene, and naphthalene are commonly found in the urine, whereas metabolites of the higher MW PAHs are generally excreted via the bile and found in the feces [7, 8] .
Recent studies have found that metabolites of lower MW PAHs are sensitive biomarkers of combustion emission exposures. More specifically, these studies have examined occupational exposures related to fire suppression, metal refining and founding, coke production and rubber manufacturing, as well as environmental exposures to PAHs in complex matrices such as urban air, cooking fumes, settled house dust and contaminated soils [9] [10] [11] [12] [13] [14] [15] [16] . Use of different PAH metabolites to discriminate between routes of exposure has also been investigated. Some studies have noted that urinary 1-OHP is a better indicator of inhalation and dermal exposures to particle-bound PAHs, whereas urinary metabolites of naphthalene and phenanthrene reflect inhalation exposures [17] [18] [19] . Therefore, assessment of multiple urinary PAH metabolites, rather than only the more commonly examined 1-OHP, may provide more insight into the exact route of PAH exposures.
The Canadian Health Measures Survey (CHMS) is a cross-sectional direct measures survey that collects data of indicators of environmental exposure, health, and nutritional status [20] . In Cycle 2 (2009-2011) of the CHMS, urinary metabolites of polycyclic aromatic hydrocarbons (PAHs) were measured in a sub-sample of the 6395 individuals surveyed (i.e., N = 2265-2524, depending on the metabolite). CHMS datasets provide an opportunity to explore empirical relationships between indicators of contaminant exposure (i.e., concentrations of chemicals in biological fluids) and demographic and/or lifestyle factors. For example, studies that examined data from CHMS Cycle 1 (2007) (2008) (2009) ) noted a significant sex-related difference in urinary concentrations of bisphenol A, and higher blood concentrations of lead in individuals of lower economic status, current or former smokers, and those who drink alcohol at least once a week [21, 22] . Although population biomonitoring data from the United States National Health and Nutrition Examination Survey (NHANES) have been used to examine relationships between urinary levels of PAH metabolites and age, sex, and smoking status, similar analyses have not been conducted using Canadian data [23] .
This study used data from a sub-sample of CHMS Cycle 2 data (i.e.,~1200 individuals aged 16 years and older) to examine empirical relationships between urinary levels of PAH metabolites and variables related to tobacco smoke exposure, population demographics, residence age, income, and occupation.
Materials and methods

Data acquisition
Data from Cycle 2 of the CHMS for 1-hydroxypyrene, 1-, 2-, 3-, 4-and 9-hydroxyphenanthrene, 1-and 2-hydroxynaphthalene, 2-, 3-and 9-hydroxyfluorene, 2-, 3-, 4-and 6-hydroxychrysene, 3-hydroxybenzo[a]pyrene and 3hydroxyfluoranthene were obtained from Statistics Canada's Health Statistics Division Data Access and Information Services (DAIS). Detailed survey methodology is available from the CHMS User Guide for Cycle 2 [24] , and in a recent overview of the biomonitoring component [20] . CHMS draws its sample from a target population representing 96% of Canadians, with exclusion of full-time members of Canadian Forces, people living on Crown lands, First Nations reserves or in other Aboriginal settlements in the provinces, residents of institutions and certain remote regions, and persons living in areas with a low population [25] . Briefly, between August 2009 and November 2011, in-home general health interviews followed by a visit to a mobile examination centre (MEC) were used to examine participants from 18 sites across Canada. More specifically, the in-home interviews collected demographic and socio-economic data and information about lifestyle, medical history, current health status, the environment, and housing conditions; the MEC visits collected blood and urine samples. Spot urine samples were collected and stored at −20°C before being shipped on dry ice. The dataset contains 6395 participants ranging in age from 3 to 79-years-old; a randomly selected subsample of the total sample population was selected for PAH metabolite analysis and only those 16 years old and older were included in this study. Analyses of the various PAH metabolites were conducted using enzymatic deconjugation and derivatization, followed by GC-MS/MS [26] .
Data analysis
Metabolite concentrations were combined by parent compound and analysed as total concentration of metabolites related to each parent compound. More specifically, pyrene produces 1-hydroxypyrene (1-OHP); 1-, 2-, 3-, 4and 9-hydroxyphenanthrenes were summed and reported as the sum of hydroxyphenanthrenes (ΣOH-Phen); 2-, 3-and 9-hydroxyfluorenes were summed and reported as the sum of hydroxyfluorenes (ΣOH-Fluo); and, 1-and 2hydroxynaphthalenes were summed and reported as the sum of hydroxynaphthalenes (ΣOH-Nap). Individuals were omitted if one or more of the metabolites in a group were less than the limit of detection or not available (i.e., "Not applicable", "Do not know", "Refusal", or "Not stated"). Importantly, <1% of most metabolite concentrations were below the limit of detection (with the exception of 9-hydroxyphenanthrene for which <6% were below the limit of detection). Thus, omitting observations for which one or more metabolites were below detection did not adversely affect the data analysis. Data from metabolites of chrysene, fluoranthene, and benzo[a]pyrene were not analysed since preliminary analysis revealed >85% of the samples were below the limit of detection (LOD).
Numerous demographic and lifestyle variables, including age, sex, occupation, income, home age, and tobacco smoke exposures (i.e., smoking status and workplace restrictions), were selected for detailed analysis. The 2001 National Occupational Classification System was used to categorize occupation [27] . A summary of the variables examined, and the associated variable levels, are provided in Table S1 . In some cases, variable levels were combined to increase the number of observations in each level and effectively improve the analyses (i.e., avoid over-stratification). The lowest level for household income was defined as <$35,000, as it was the approximate 2009 low-income cutoff [28] . The upper level for household income (i.e., ≥$80,000) is the level associated with the top 10% of Canadians [29] . Age was categorized as young adult (i.e., [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , adult (i.e., , and senior (≥50). Individuals under 16 years old were omitted from analyses due to the fact that the majority of individuals under 16 responded "not applicable" for their smoking status, occupation, and work smoke restrictions (i.e., 94-98%). Furthermore, differences in urinary creatinine concentrations between children and adults would hamper meaningful comparisons of urinary PAH metabolite levels [30] . Where values were reported as "Not applicable", "Do not know", "Refusal", and "Not stated", observations were omitted unless they represented >5% of the observations for a particular variable, in which case an additional category labelled "N/A" was added and included in the analyses. For example, the Work Smoking Restrictions variable has three levels, "Limited restrictions", "Restricted", and "N/A". The first level includes "Some Restrictions" and "No Restrictions", the second includes "Restricted" and "Designated Areas Only", and the "N/A" category includes "Not applicable", "Do not know", "Refusal", and "Not stated". Similarly, Occupation also has an "N/A" variable category ( Table 1) .
Urinary levels of each PAH metabolite, expressed as µg per g creatinine, were defined as dependent variables, and the effects of the variables listed in Table 1 were examined using SAS v9.4 for Windows 7 (SAS Institute, Cary, NC, USA). Creatinine correction was used to account for sample dilution variation driven by differences in urinary flow rate (i.e., dilution of urine). We used creatinine-corrected metabolite levels as the dependent variables since an earlier study showed similar results when urinary creatinine was included as an independent variable in the statistical models [31] . Urinary metabolite levels were log transformed to equalise the variance across the range of observations, thereby meeting the assumption of the statistical methods employed. Multicollinearity of the independent variables was assessed by visual inspection of a correlation matrix, and examination of collinearity diagnostics. More specifically, the variance inflation factor (VIF) and tolerance of each predictor variable was determined and evaluated using the criteria indicated by Allison [32] and Schreiber-Gregory and Jackson [33] . Empirical relationships were investigated using PROC SURVEYREG, a procedure specifically designed for regression analysis of survey data. PROC SURVEYFREQ procedure was used to examine correlations using the Pearson Chi-Square test and PROC SURVEYMEANS was used to calculate descriptive statistics. Standard errors of geometric means were calculated as defined by Wolter (1985) [34] . WEIGHT and REP-WEIGHTS statements were used in all three procedures to incorporate recommended weighting factors that adjust for subject selection [24] . The VARMETHOD statement was also used to specify the balanced repeated replication (BRR) method as the variance estimation model. Forward and backward variable selection was used to determine the most parsimonious model relating the selected independent variables to urinary PAH metabolite levels. Variable selection employed a PROC SURVEYREG SAS macro developed by Wang and Shin [35] . Briefly, the procedure involved iterative inclusion (i.e., forward) or exclusion (i.e., backward) of variables, with the F statistic being used to evaluate sequential model improvement. Variable significance for model entry and removal was set to p < 0.05.
Results and discussion
Descriptive statistics for each urinary metabolite, compiled across the various levels of the independent variables examined, are summarised in Table 1 . Differences in the sample sizes arose when observations were omitted due to inability to calculate metabolite sums (i.e., one or more of the metabolite values were not available). Highest geometric means (GM) for all metabolite groups were associated with individuals who are smokers and have a household income of <$35,000. Relative geometric means for categories of work smoke restrictions, sex, age, age of home, and occupation were less conclusive (i.e., varied between categories and metabolites). Thus, it is evident from the descriptive statistics alone that several factors are empirically related to urinary PAH metabolite concentrations. Table 2 summarises the results of the stepwise model selection analyses. The results obtained reveal that the variables investigated can explain between 24% and 52% of the variation in urinary levels of the PAH metabolites investigated. In the forward and backwards models, age was the second most influential variable for all metabolites except ΣOH-Nap. Though less influential, sex was also a significant predictor of PAH metabolite concentrations, in addition to age of home for ΣOH-Fluo concentrations ( Table 2) . For all metabolites, the forward and backward procedures yielded nearly identical results.
Because smoking status has a consistent and marked influence on urinary PAH metabolite concentrations, analysis of a non-smoker dataset was employed to further scrutinise empirical relationships with other variables ( Table 3 ). The results revealed that the other variables can explain 6-9% of the variation in PAH metabolites levels in non-smokers' urine. Age and sex were significant predictors for 1-OHP, ΣOH-Phen and ΣOH-Nap, whereas age of home was significant for ΣOH-Phen and ΣOH-Fluo. Workplace smoking restrictions and occupation were significant predictors in the backward model for ΣOH-Fluo and ΣOH-Nap. This is likely linked to second-hand smoke exposure. For non-smokers only, the variable explaining the most variability was sex for ΣOH-Nap (i.e., 7%). Overall, analysis of the non-smoker data revealed several interesting, statistically significant variables (e.g., occupation, sex, home age, and age).
Prior to interpreting the aforementioned results (see below), it should be noted that collinearity amongst the independent variables (e.g., smoking status, occupation, age, etc.) will influence the results obtained for any model with more than one independent variable (i.e., the results will depend on the order in which the variables are entered into the model). Indeed, the correlation matrix for the independent variables, which is presented in Table S2 , revealed multicollinearity for most of the variables examined. However, inspection of VIFs and tolerance values for each predictor revealed that, with the exception of the variables for workplace smoking restrictions and occupational classification, multicollinearity is not problematic. More specifically, VIF values for all other predictor variables were <2.0, corresponding to r 2 values < 0.50. Tolerance values for all other predictor variables were far greater Summary is based on Cycle 2 (2009-2011) of the CHMS data, and values are presented for the various levels of the independent variables examined (Table S1) .
Values with a different superscripted letter are significantly different at p < 0.05. N/A not applicable or not stated, GM geometric mean, N unweighted sample size. than 0.1. This contention is supported by the fact that the different model selection procedures (i.e., forward and backward) often yielded the same results. Although dataset partitioning could have been used to more rigorously account for multicollinearity amongst the independent variables, this approach would have resulted in overstratification of the dataset, with consequent declines in observation number and statistical power.
Effects of tobacco smoke exposure
Tobacco smoke can be a major source of PAH exposure, with up to thousands of nanograms of PAHs being produced during the combustion of a single cigarette [36] . With cigarette smoking recognised as the leading cause of preventable disease, and various PAHs in tobacco smoke recognised as possible, probable, or known human carcinogens, assessment of tobacco smoke-derived PAH exposures is an important endeavour [37, 38] . Although urinary PAH metabolites have been used to investigate individuals' tobacco smoke exposure, the utility of specific PAH metabolites is less understood [39] [40] [41] [42] [43] . Here, not surprisingly, the levels (i.e., GMs) of all four PAH metabolite groups were elevated in tobacco smoke-exposed individuals, in comparison with non-smokers ( Table 1 , Fig. 1 ). Moreover, in comparison with the other variables examined, smoking status was the best explanatory variable (i.e., across all models presented in Table 2 ), accounting for 19-50% of the variability in the dependent variables (i.e., urinary metabolite levels).
The effect of smoking status on the levels of each metabolite group was also investigated. This analysis was used to determine if specific PAH metabolites may be superior better biomarkers of tobacco smoke exposure than other PAH metabolites, and thus better indicators of PAH source [37, 45] . Indeed, personal smoking habits accounted for more of the variance in ∑OH-Fluo levels (50%), in comparison with ∑OH-Nap, 1-OHP and ∑OH-Phen (i.e., 29, 27, 19%, respectively, Table 2 ). This is consistent with St. Helen et al. [2] who noted significant relationships between urinary 1-hydroxyfluorene and both smoking status and the concentration of a urinary nicotine metabolite [2] . Thus, the results obtained here and elsewhere suggest that, in comparison with other urinary PAH metabolites, metabolites of fluorene may be better biomarkers of tobacco smokederived PAH exposures. Nevertheless, it is important to note that the respective variance proportions may be related to the relative amounts of the parent PAHs in tobacco smoke. More specifically, compared to phenanthrene and pyrene, fluorene is more abundant in mainstream cigarette smoke [37] . Because individuals spend a considerable amount of their time in the workplace, relationships between workplace smoking restrictions and urinary PAH metabolites were also investigated. To the best of our knowledge, this is the first study to examine relationships between urinary PAH metabolite levels and reported workplace smoking restrictions. The results indicate that individuals at workplaces with Limited Restrictions (i.e., no or some smoking restrictions) had the highest GM values for 1-OHP, ∑OH-Fluo and ∑OH-Nap, but values were only significantly different for 1-OHP ( Fig. 1, Table 1 ). With respect to the stepwise analysis, workplace smoking restrictions was only significant in the backwards selection models for ∑OH-Fluo and ∑OH-Nap in the non-smoker dataset ( Table 3 ). This suggests that although metabolites of fluorene appear to be superior biomarkers of tobaccoderived PAHs, they may not be reliable, effective biomarkers of workplace tobacco smoke exposure.
It is important to note that correlations between Workplace Smoking Restrictions and the other independent variables investigated (i.e., smoking status, age, sex, age of home, and occupation, Comparative evaluations regarding the utility of different urinary biomarkers to assess PAH exposures associated with a personal smoking habit of substances other than tobacco are of significant interest, particularly considering the recent legalisation of cannabis use in Canada. Future work should investigate the relationship between cannabis use and urinary PAH metabolite levels. Such work would follow-up on studies such as that conducted by Wei et al. [44] , which showed a significant increase in the urinary levels of several monohydroxy PAHs in recent cannabis users [44] .
Effects of demographic and lifestyle factors
The influence of demographic and lifestyle factors, such as sex, age, income, and age of home, on PAH exposure and urinary metabolite levels are less intuitively obvious. After suitably accounting for the confounding and more predominant effects of smoking status and/or age and/or occupation, sex appeared to be significantly related to urinary levels of PAH metabolites (Tables 2 and 3 ). In addition, the ∑OH-Nap results indicated that females have significantly higher urinary metabolite concentrations (p < 0.05, Table 1 ). These results are consistent with biomonitoring results for several other substances. For example, analysis of data from Cycle 1 (2007-2009) of the CHMS revealed significantly higher concentrations of several compounds in the biological fluids of Canadian women, in comparison with Canadian men (i.e., cadmium, manganese, p,p′-dichlorodiphenyltrichloroethane, hexachlorobenzene, and β-hexachlorocyclohexane) [21] .
It is not clear what is driving the above-mentioned effect of sex on urinary levels of PAH metabolites (i.e., Tables 1  and 3 ), particularly levels of ∑OH-Nap (Table 1 ). Since women have been shown to, on average, produce less creatinine relative to men [30] , observed differences (e.g., for ∑OH-Nap and ∑OH-Phen) may be related to a creatinine-correction gender-bias. It is also possible that traditional gender roles alter exposures to combustion emission sources that are not related to tobacco smoke (e.g., diet, food preparation, time spent outdoors, use of incense) [3, 42, [46] [47] [48] [49] [50] . Alternatively, there may be sex-related differences in absorption, metabolism, storage, and excretion of PAHs [51] [52] [53] . For example, females have been reported to exhibit higher expression of genes encoding PAH metabolising enzymes (i.e., CYP1A1); it has even been suggested that women's elevated enzymatic capacity increases their susceptibility to DNA adduct formation and lung cancer [52, 54] . Thus, consideration of sex when comparing urinary PAH metabolite levels within a population is important. Ultimately, if the observed sex-specific effects are robust, and females are indeed experiencing higher exposures to individual PAHs or PAH mixtures, identification of the putative sources is of utmost importance. To robustly investigate the effect of sex on urinary levels of PAH metabolites in Canadians, future work should examine a dataset that is balanced with respect to sex, age, smoking status and occupation. This is particularly pertinent for metabolites of naphthalene.
The results obtained also revealed significant relationships between age and urinary PAH metabolite levels (Tables 1-3) ; the relationship varied across the metabolites examined. For example, Table 1 shows that individuals ≥50 years old had significantly lower levels of 1-OHP, but significantly higher levels of ∑OH-Phen, compared to the other two age categories (p < 0.05). Urinary ∑OH-Fluo concentrations in those 16-25-year-old were found to be significantly lower than the other two age categories (p < 0.05). The influence of age-related activities on urinary PAH metabolites certainly warrants further investigation.
The results presented in Table 1 and Fig. 1 also show differences in the GMs of the various urinary PAH metabolites for different categories of household income and home age. With respect to household income, the highest GM across all metabolites was associated with individuals with a yearly household income of less than $35,000 per year. Moreover, with the exception of 1-OHP, as income increased there was a decrease in urinary PAH metabolite concentrations. This is consistent with previous findings indicating that low-income individuals experience increased PAH exposures related to poor air quality, which in turn is likely influenced by home location (i.e., proximity to industry or heavy traffic), and levels of environmental tobacco smoke [55] . It is important to note that smoking status may also be driving this relationship; higher smoking rates having been previously noted in low-income individuals relative to higher socioeconomic status individuals [56] [57] [58] [59] . Indeed, careful scrutiny of the analysed data revealed nearly three times the number of non-smokers in households with incomes ≥$80,000 a year compared to those with incomes <$35,000 a year. Despite the observed income status trend, the iterative model selection procedure failed to include household income for the data sets with and without smoking status (Tables 2 and 3 ). This is not surprising given the strong correlations between household income and each of the other independent variables except sex (Table S2 ). Thus, the unbalanced nature of the data and the degree of correlation between income and other variables prohibited robust assessment of the influence of household income on urinary PAH metabolite levels. Using an appropriately balanced dataset, a future study could investigate the effect of household income above and beyond the aforementioned demographic and lifestyle factors.
A significant effect of home age was also observed, and the results summarised in Table 2 and Fig. 1 indicate that those who live in the oldest homes (i.e., ≥50 years) have the highest GM levels of PAH metabolites. Iterative model selection revealed significant, robust effects of home age on ∑OH-Fluo (Table 2) , and in the non-smoker dataset for ∑OH-Phen and ∑OH-Fluo (Table 3 ). This result is consistent with previously published observations showing that household dust samples from older homes have significantly higher PAH levels. It is also possible that individuals in older homes are exposed to higher levels of PAHs associated with older styles of residential heating (e.g., wood and wood pellets). Several studies have shown differing levels of PAHs in homes using different heating sources. More specifically, higher PAHs in homes heated using wood in old-style wood boilers, compared to other heating sources (i.e., wood stoves, modern wood boilers, pellet burners, and oil). Several studies have shown differing levels of PAHs in homes using different heating sources [60] [61] [62] . Unfortunately, the low frequency of households using wood burning stoves and fireplaces restricted the ability to investigate the effect of home heating style on urinary metabolite levels. Lastly, home age may also be a surrogate for location. Older homes are most often located in more congested urban centres that likely have higher traffic density and higher levels of PAH-contaminated airborne particulate matter. Nevertheless, it seems clear that home age has a significant, albeit relatively weak effect on urinary levels of ∑OH-Fluo and ∑OH-Phen.
Effect of occupation
Certain occupations have been associated with increased levels of PAH exposures [11, 12, [63] [64] [65] [66] [67] [68] [69] [70] [71] . Investigations regarding the influence of occupation on urinary levels of PAH metabolites can permit the identification of problematic occupational settings that require intervention to improve worker health and safety. For example, compared to controls, individuals working in the aluminum industry and aluminum electrolysis anode-manufacturing facilities have been shown to have significantly elevated levels of urinary PAH metabolites [72] [73] [74] [75] . The results obtained here indicate that individuals with Blue Collar occupations have higher concentrations of urinary PAH metabolites compared to individuals with White Collar occupations ( Table 1 , Fig. 1 ). Only backwards model selection for the non-smoker dataset revealed a significant effect of occupation on urinary concentrations of ∑OH-Fluo and ∑OH-Nap, after controlling for work smoke restrictions and age of home for ∑OH-Fluo, and work smoke restrictions, age of home, and sex for ∑OH-Nap (Table 3 ). This likely reflects robust differences in occupational exposures to some PAHs. Nevertheless, it should be noted that the effect of occupational classification may be confounded with effects related to tobacco smoke exposure, sex, age, and household income. This contention is supported by Canadian and American studies that noted relationships between occupation and smoking status, which increases the difficulty of detecting robust occupational effects that are not confounded with the increased smoking rates observed in Blue Collar cohorts [76, 77] . Although the analyses presented herein did reveal a significant effect of occupation, it is clear that robust investigation of occupational effects requires careful control of confounding variables.
Limitations
The variables examined here explained 24-52% of the variation in the levels of the various PAH metabolites ( Table 2) , leaving 48-76% of unexplained variation. A substantial portion of this unexplained variation is likely accounted for by dietary intake. This is consistent with studies which noted that, for non-smoking, nonoccupationally exposed individuals, dietary intake is considered a major route of PAH exposure [3] . Although diet is known to account for a substantial portion of total daily PAH exposure, and the CHMS does include basic information about food choices and consumption, this study did not examine relationships between urinary metabolite levels and dietary habits and activities. This is primarily due to known challenges related to the quantification of PAHs in foods, and the determination of dietary intake via food consumption recall questionnaires. The accuracy and utility of such questionnaires are known to be hindered by significant reporting biases and errors, with individuals often underreporting food consumption, sometimes at implausibly low intake levels when compared with estimated energy needs [78] [79] [80] [81] . For example, one recent study found that 70% of individuals reported dietary habits that disagreed with results from stool analysis [82] . Thus, due to the aforementioned skewed nature of the dataset, and the requirement for precise dietary intake data, the relationships between dietary habits and urinary PAH metabolite levels could not be reliably investigated herein. Nevertheless, targeted follow-up analyses could investigate the influence of diet on urinary levels of PAH metabolites; moreover, the magnitude of the effects relative to those delineated in this work. Such studies could be based on population data or more controlled diet studies.
Creatinine is often used as an indicator of dilution in urinary biomarker analyses, including analyses of CHMS biomonitoring data [31, 83, 84] . The traditional and commonly used approach simply divides the concentration of the analyte by the urinary concentration of creatinine, thereby providing concentration values expressed by unit creatinine. A previous study of CHMS urinary PAH metabolite data by Cakmak et al. [83] compared two approaches for creatinine adjustment, i.e., creatinine adjustment of metabolite concentration values, and inclusion of creatinine concentration in the statistical model(s) examined. The authors noted that both approaches produced similar results [83] . Thus, in the context of the current study, it was reasonable to conduct the analyses using creatinine-corrected PAH metabolite values, i.e., values expressed as metabolite per unit urinary creatinine. It is also important to emphasise that since urinary metabolite concentrations in the available CHMS data were already creatinine-corrected (i.e., expressed per unit creatinine), and other metrics indicative of urinary dilution were not available, it was not possible to investigate the utility of alternative metabolite correction approaches (e.g., correction using urinary output information, osmolality, or specific gravity). Nevertheless, it should be noted that creatinine production can differ across age, sex, and race, and uniformly applied creatinine-based adjustments for urinary dilution can affect the interpretation of data analyses such as those conducted herein [30] . In other words, although the creatinine correction approach is pervasive in the biomonitoring literature, it may not be the ideal method to adjust for urinary dilution, particularly for biomonitoring studies that encompass a range of demographic and ethnic groups. Recent studies have suggested that osmolality (i.e., concentration of solutes in solution) is a superior metric to adjust biomonitoring data for differences related to hydration [85] . Biomonitoring programs, and future studies examining empirical relationships in biomonitoring data, should consider the use of osmolality for urinary dilution adjustment.
Despite the conclusions of the aforementioned Cakmak et al. [83] study, the data examined herein can alternatively be analysed using uncorrected metabolite concentration as the dependent variable and urinary creatinine concentration as an explanatory variable in the regression models. These additional analyses confirmed most of the explanatory variable effects listed in Table 2 . Nevertheless, there were some inconsistencies between the two data analysis approaches, and these differences need to be acknowledged. More specifically, the alternative analysis approach could not confirm the effects of age on ∑OH-Phen, age and age of home for ∑OH-Fluo, and sex on ∑OH-Nap. Since the r 2 values associated with models that examined these effects on creatinine-corrected metabolite levels are all below 0.03 (Table 2) , it can be concluded that these weak effects would need to be confirmed by subsequent analyses of biomonitoring data.
It is important to note that statements regarding the utility of any particular urinary metabolite to assess PAH exposures from particular sources will be affected by multicollinearity amongst the dependent variables (e.g., 1-OHP and ∑OH-Phen). Consequently, collinearity amongst the metabolite variables was also assessed; the results revealed low to moderate correlations (i.e., Pearson r < 0.7), except for between ∑OH-Phen and ∑OH-Fluo (i.e., Pearson r = 0.79, Table S3 ). Furthermore, correlation analysis of the residuals associated with the models described in Table 2 , which are summarised in Table S4 , also showed low to moderate correlations (i.e., Pearson r ≤ 0.6) for all but ∑OH-Phen and ∑OH-Fluo (i.e., Pearson r = 0.77). Because residuals associated with the phenanthrene and fluorene metabolite models were noticeably more correlated than the others, it is difficult to confidently state that the described empirical relationships for each metabolite are unique. However, the magnitude of the Pearson coefficients for nearly all the correlations between model residuals would not be considered severe (i.e., <0.7). Nevertheless, future work should consider the use of other alternative methods to handle dependent variable collinearity. For example, principal component analysis (PCA) could be used to derive a metabolite score for each individual, with subsequent analyses examining empirical relationships between the independent variables and unique axis scores.
Conclusions
Urinary PAH metabolites permit identification of groups within a population that may have an enhanced risk of effects related to PAH-exposure. The analyses here identify demographic and lifestyle variables that influence PAH metabolite levels in a nationally representative sample of Canadians over 16 years old. With respect to the utility of the various PAH metabolites as biomarkers of PAH exposure, the results suggest that some of the PAH metabolites may be particularly useful for examination of particular exposure scenarios. For example, the results revealed that smoking status has a stronger influence on ∑OH-Fluo (i.e., higher partial r 2 ) as compared with 1-OHP, ∑OH-Phen, and ∑OH-Nap. Thus, it is reasonable to assert that 1-OHP, the traditional PAH biomonitoring tool, may not be effective for all exposure scenarios; and moreover, that other metabolites may be more suitable for selected exposure scenarios (e.g., ∑OH-Fluo for tobacco smoke exposure). Nevertheless, as noted, collinearity of the dependant variables complicates rigorous evaluations regarding the utility of individual metabolites to monitor specific types of exposures.
The results presented herein highlight the need for follow-up studies that continue to scrutinise the relationships between urinary PAH metabolite levels and lifestyle and demographic variables; moreover, studies that highlight PAH sources that can be controlled and/or avoided. Similar analyses should be conducted using other population survey datasets and should consider improved methods of urinary dilution correction factors. Lastly, it should prove interesting to investigate the post-legalisation relationship between cannabis use and urinary PAH metabolite levels, particularly for individuals who do not use tobacco. Ultimately, the results presented in this study, when combined with robust follow-up studies, contribute to improved understanding regarding the determinants of PAH exposure, thus allowing for effective exposure reduction and risk mitigation.
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